69% risk reduction of CAUTI with Bactiguard’s Technology
A large, randomized, controlled multicenter study in India with 1,000 patients included, published in the internationally renowned scientific journal “Antimicrobial resistance and infection control”, shows that urinary catheters with Bactiguard’s coating for infection prevention reduce the risk of catheter-associated urinary tract infections (CAUTI) by 69 % compared to standard catheters.1
BIP Foley TempSensor is an indwelling urinary catheter which combines continuous temperature monitoring with Bactiguard’s infection prevention technology. A great benefit to patients in intensive care, surgery and other conditions where continuous temperature monitoring is critical in monitoring the health status and wellbeing of the patient.
The unique Bactiguard technology reduces microbial adhesion on the catheter
The Bactiguard infection prevention technology is based on a very thin noble metal alloy coating firmly attached to the catheter surface. When in contact with urine, the noble metals create a galvanic effect which reduces microbial adhesion to the catheter material. Fewer adhesion decreases the risk of biofilm formation leading to infection.
Increased patient safety for critically ill patients
BIP Foley TempSensor offers both infection prevention and surveillance in one product, a great benefit for patients in intensive care, surgery and other conditions where continuous temperature monitoring is critical in monitoring the health status and wellbeing of the patient. The Bactiguard coated catheter is equipped with an extra channel that contains a temperature sensor that is connected to an external monitor and connects to suitable 400 Series patient monitor.
Product details
Bactiguard coating on both inside and outside of the catheter
Hydrophilic coating reduces friction and increases patient comfort
References 1. Kai-Larsen et al. Foley catheter with noble metal alloy coating for preventing catheter-associated urinary tract infections: a large, multi-center clinical trial. Antimicrob Resist Infect Control 10, 40 (2021).